Glutamate Metabotropic Receptor 7 (GRM7) Antibody

Background

GRM7, or mGluR7, is a Group III metabotropic glutamate receptor widely expressed in the central nervous system, including the hippocampus, amygdala, and cerebellum. It functions as a presynaptic autoreceptor, coupling to Gi/o proteins to inhibit adenylate cyclase, decrease cAMP production, and suppress glutamate release. GRM7 plays a key role in synaptic plasticity, neuroprotection, and neuronal excitability, contributing to learning, memory, and emotional regulation. Dysregulation of GRM7 signaling is linked to psychiatric and neurological disorders, including anxiety, depression, schizophrenia, and epilepsy, where imbalanced glutamatergic transmission disrupts synaptic function. GRM7 activation has neuroprotective effects, reducing excitotoxicity and oxidative stress in neurodegenerative conditions. Positive allosteric modulators (PAMs) and selective agonists of GRM7 are being explored as therapeutic agents for anxiety, mood disorders, and epilepsy, highlighting its potential in restoring synaptic balance and neuroprotection.